Drug Trial Radar · NCT02924727
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,669
Actual
Start
Dec 9, 2016
Primary completion
Feb 26, 2021
Study completion Feb 26, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
Conditions
- Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan)Drug
LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
RamiprilDrug
Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
Placebo of LCZ696Drug
Matching placebo of LCZ696 tablets
Placebo of ramiprilDrug
Matching placebo of ramipril capsule
ValsartanDrug
Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
Placebo of valsartanDrug
matching placebo of valsartan for one day to patients who will be randomized to received ramipril
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First CEC (Clinical Endpoint Committee) Confirmed Primary Composite EndpointTime frame: From randomization to first occurrence (up to approximately 43 months)
Locations
486 sites in 41 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Gilbert, Arizona
Novartis Investigative Site
Bakersfield, California
Novartis Investigative Site
Carmichael, California
Novartis Investigative Site
Los Alamitos, California
Novartis Investigative Site
Northridge, California
Novartis Investigative Site
Orange, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Sylmar, California
Novartis Investigative Site
Brandon, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville Beach, Florida
Novartis Investigative Site
Ocala, Florida
Novartis Investigative Site
Cumming, Georgia
Novartis Investigative Site
Johns Creek, Georgia
Novartis Investigative Site
Thomasville, Georgia
Novartis Investigative Site
Boise, Idaho
Novartis Investigative Site
Coeur d'Alene, Idaho
Novartis Investigative Site
Muncie, Indiana
Novartis Investigative Site
Munster, Indiana
Novartis Investigative Site
Richmond, Indiana
Novartis Investigative Site
Iowa City, Iowa
Novartis Investigative Site
Alexandria, Louisiana
Novartis Investigative Site
Baton Rouge, Louisiana
Novartis Investigative Site
Covington, Louisiana
Novartis Investigative Site
Hammond, Louisiana
Novartis Investigative Site
Slidell, Louisiana
Novartis Investigative Site
Bangor, Maine
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Rockville, Maryland
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Kalamazoo, Michigan
Novartis Investigative Site
Lansing, Michigan
Novartis Investigative Site
Petoskey, Michigan
Novartis Investigative Site
Saginaw, Michigan
Novartis Investigative Site
Southfield, Michigan
Novartis Investigative Site
Duluth, Minnesota
Showing 40 of 486 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.